Cohance Lifesciences Limited (BOM:543064)
India · Delayed Price · Currency is INR 451.55
+10.95 (2.49%)
At close: Jul 10, 2026
Cohance Lifesciences Market Cap
Cohance Lifesciences has a market cap or net worth of 172.88 billion as of July 13, 2026. Its market cap has decreased by -54.39% in one year.
Market Cap
172.88B
Enterprise Value
174.85B
Revenue
22.69B
Ranking
n/a
PE Ratio
96.46
Stock Price
451.55
Market Cap Chart
Since March 9, 2020, Cohance Lifesciences's market cap has increased from 33.71M to 172.88B, an increase of 512,827.13%. That is a compound annual growth rate of 284.78%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 10, 2026 | 172.88B | -14.51% |
| Dec 31, 2025 | 202.22B | -30.24% |
| Dec 31, 2024 | 289.89B | 57.55% |
| Dec 29, 2023 | 184.00B | 46.05% |
| Dec 30, 2022 | 125.98B | 0.33% |
| Dec 31, 2021 | 125.56B | 9.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Mar 9, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| GlaxoSmithKline Pharmaceuticals | 412.59B |
| J. B. Chemicals & Pharmaceuticals | 391.39B |
| Rubicon Research | 235.82B |
| Granules India | 220.43B |
| AstraZeneca Pharma India | 203.10B |
| Caplin Point Laboratories | 196.52B |
| Jubilant Pharmova | 152.20B |
| CORONA Remedies | 124.94B |